United Capital Research | Daily Market Commentary

Tuesday, January 12, 2021



The Intelligent Choice

The day in review

- Equities market sustains gains
- Financial system liquidity remained robust
- · Bearish activity in FI market
- Naira depreciated at the NAFEX window

Looking forward

• PMA Auction - 14th Jan

Daily Insight

Covid-19 vaccines vs 2nd wave of infections

2020 showed that full economic recovery would prove to be impossible without a vaccine. At the onset of the coronavirus outbreak, some governments had mulled the idea that herd immunity would be the preferred strategy to avoid a total shutdown of global economies. That strategy proved to be disastrous as the UK, one of the countries that championed this idea, became the epicenter of the pandemic in Western Europe.

In Q4 2020, Pfizer and BioNTech, Moderna and AstraZeneca, in collaboration with Oxford University, announced effective vaccines for Covid-19. According to scientists, about 70% of the population must be vaccinated for a vaccine-induced herd immunity to be effective. As such, the speed of approval by government regulators and the massive deployment of vaccines to ensure that they reach the poorest parts of the world would be critical. This position is extremely important within the context of the 2nd wave of coronavirus infections in many advanced economies, as well as some emerging and frontier markets. For instance, aside from the US and most of Europe, which are already dealing with the 2nd wave of infections, Nigeria, S/Africa, Pakistan, Israel, S/Korea amongst others have confirmed a worrying level of new cases, suggesting a 2nd wave.

As such, we believe that Covid-19 remains a major threat in 2021, albeit with a brighter outlook in light of vaccine developments. Accordingly, we are of the view that global recovery in 2021 hangs on the balance between the severity of the 2nd or 3rd wave of infections and the speed and efficacy of vaccination.

Headline	Level	1 day	YTD
NSE ASI	40,296.0	0.4% 📤	0.1%
Mkt. Cap (₦'bn)	21,070.0	-1.8% 📤	0.1%
Mkt. Cap (\$'mn)	55,593.5	-1.8% 📤	0.1%
Value (N'mn)	7,969.9	-61.9%	
Value (\$'mn)	21.0 🔻	-61.9%	
Volume	1,166.4 📤	247.5%	
Deals	5,591.0 📤	4.7%	
Market Breadth	1.3x		

T-Bills Yields	Current	Previous	%∆
3 months	0.26	0.17 📤	0.09
6 months	0.46	0.39 📤	0.07
12 months	1.90	0.93 📤	0.97
Bonds Yields	Current	Previous	% △
3 years	3.52	3.45 📤	0.07
5 years	5.55	5.50 📤	0.05

6.52

7.69

Currencies	Current	Previous	% L
Official	379.00	379.00 💳	0.009
Parallel	472.50	471.50 🔻	-0.219
NAFEX	394.00	393.30 🔻	-0.18%

7 years

10 years

Other Key indices	Current	Previous	% △
OBB	3.0	2.5 📤	0.50
OVN	3.5	3.3 📤	0.25
Brent	56.6	55.7 📤	1.65

	1 day	MTD	YTD	P/E (x)	Div. Yid.
Agriculture	- 0.0%	— 0.0% =	0.0%	0.0	0.0%
Banks	3.7%	△ 3.7% △	3.7%	4.2	8.5%
Consumer	1.4%	1.4% 🚄	1.4%	863.6	3.8%
Industrial	4.7%	▲ 4.7% ▲	4.7%	22.3	0.0%
Insurance	4.4%	▲ 4.4% ▲	4.4%	3.0	2.3%
Oil & Gas	0.1%	△ 0.1% △	0.1%	83.1	6.1%
	Mkt. Avg. P/E	15.5	Mkt.	Avg. Div. Yid	4.5%

*P/Es are based on the last twelve months trailing earnings

*Dividend vields are based on past year dividend payment

Technical Indicator of Market Position: Relative Strength Index (RSI)				
	M.	Overbo	aught region 100 80	
Lyph			60 40	
Oversø	d region WW)	20	
30/2019	1/30/2020	7/30/2020	1/12/2021	

Pan African Market Monitor as at today						
Equities	Level	1 day	YTD	P/E (x)	Div. Yid.	
BRVM	141.6 🔷	-2.6% 🔻	-2.6%	8.7	6.7%	
Egypt	10,813.8 🔻	-0.3% 🔻	-0.3%	11.6	2.9%	
Ghana	1,941.6 📥	0.1% 📤	0.1%	n/a	4750.4%	
Kenya	152.0 🔻	0.0% 🔻	0.0%	11.3	4.4%	
Mauritius	1,644.1 🔷	-0.3% 🔻	-0.3%	n/a	2.3%	
Morocco	304.9 📥	0.8% =	0.0%	30.6	3.1%	
MSCI FM	551.1 💳	0.0% 📤	0.0%	12.8	3.4%	
South Africa	60,479.4 📥	1.8% 📤	1.8%	27.6	2.6%	
Tunisia	6,808.1 🔻	-1.1% 🔻	-1.1%	20.6	0.6%	
Zimbabwe	46,327.4 💳	0.0% 💳	0.0%	0.9	2.4%	


Rate of Vaccine Coverage pre ordered from Pfizer/BioNtech. Moderna and Astrazeneca/Oxford Vaccine preorders heavily skewed towards rich countries

6.53

7.58

-0.01

0.11



Sources: Company website, United Capital Research

Contact us

Research | +234-1-631-7898 research@unitedcapitalplcgroup.com

Trustees | +234-1-631-7877

trustees@unitedcapitalplcgroup.com

Securities Tradina | +234-1-631-7891 securities@unitedcapitalplcgroup.com

Investment Bankina | +234-1-631-7883

investmentbanking@unitedcapitalplcgroup.com

Asset Management | +234-1-631-7876

assetmanagement@unitedcapitalplcgroup.com

United Capital Plc Research (UCR) notes are prepared with due care and diligence based on publicly available information as well as analysts' knowledge and opinion on the markets and companies covered; albeit UCR neither guarantees its accuracy nor completeness as the sole investment auidance for the readership. Therefore, neither United Capital (UCAP) nor any of its associates or subsidiary companies and employees thereof can be held responsible for any loss suffered from the reliance on this report as it is not an offer to buy or sell securities herein discussed. Please note this report is a proprietary work of UCR and should not be reproduced (in any form) without the prior written consent of Management. UCAP is registered with the Securities and Exchange Commission and its subsidiary, UBA Securities Limited is a dealing member of the Nigerian Stock Exchange. For enquiries, contact United Capital Plc, 3rd and 4th Floor, Afriland Towers, 97/105 Broad Street, Lagos. @ United Capital Plc 2020.*